Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

Autor: Pancholi, Sunil, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Nikitorowicz-Buniak, Joanna, Ressa, Anna, Gao, Qiong, Leal, Mariana Ferreira, Bhamra, Amandeep, Thornhill, Allan, Morisset, Ludivine, Montaudon, Elodie, Sourd, Laura, Fitzpatrick, Martin, Altelaar, Maarten, Johnston, Stephen R, Marangoni, Elisabetta, Dowsett, Mitch, Martin, Lesley-Ann, Afd Biomol.Mass Spect. and Proteomics, Biomolecular Mass Spectrometry and Proteomics

Publikováno v: Oncogene, 39(25), 4781. Nature Publishing Group
Oncogene

Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than loss ofRB1few gene-copy number

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83726164166fa3f899deca8969edd34c
https://doi.org/10.1038/s41388-020-1284-6

Enzalutamide therapy for advanced prostate cancer

Autor: Henk G. van der Poel, Stefan Prekovic, Andries M. Bergman, Wilbert Zwart, Simon Linder

Publikováno v: Endocrine-Related Cancer
Endocrine-related cancer, 26(1), R31-R52. BioScientifica Ltd.

The androgen receptor drives the growth of metastatic castration-resistant prostate cancer. This has led to the development of multiple novel drugs targeting this hormone-regulated transcription factor, such as enzalutamide – a potent androgen rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::357bc7afdab1ba7fb514f96f883fe2d1
https://research.tue.nl/en/publications/e684cbca-aa8a-4687-a92c-cecbb6d86f63

MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance

Autor: Marcel Spaargaren, Tomohiro Mizutani, Steven T. Pals, Hans Clevers, Sander P.J. Joosten

Publikováno v: Gastroenterology, 157(4), 1153-1155.e1. W.B. Saunders Ltd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c11f9ac4cec677bb1e247ed0ae31e5f
https://pure.knaw.nl/portal/en/publications/09dac440-1221-4d76-826c-d3f17ce4e1b4

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Autor: Catherine Jane Bale, Rachel Butler, S Waters, Angela C. Casbard, Sarah Moon, Andrew Foxley, Ramachandran Venkitaraman, Catrin Cox, Johnathan Joffe, Tracie-Ann Madden, Fouad S Alchami, Margherita Carucci, Robert H. Jones, Chris Twelves, Pavel Bezecny, Sacha J Howell

Publikováno v: Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4

Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of, the serine/threonine kinase, Akt. Akt inhibitors are anticipated to have maximal efficacy in combination with chemotherapy, targeted, or anti-hormonal dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e1775f72f2c39bba92c189237cd97
https://pubmed.ncbi.nlm.nih.gov/32359499

Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment

Autor: Thomas Sauter, Eivind Valen Egeland, Kjetil Nordbø Jørgensen, Marco Vincent Haselager, Kotryna Seip, Olav Engebraaten, Gunhild Mari Mælandsmo, Mads H. Haugen, Philippe Lucarelli, Lina Prasmickaite, Marco Albrecht

Publikováno v: Cancer Letters
Cancer letters. Ireland (2018).
Cancer letters, 439, 1-13. Elsevier Ireland Ltd

Cancer cells' phenotypic plasticity, promoted by stromal cells, contributes to intra-tumoral heterogeneity and affects response to therapy. We have disclosed an association between fibroblast-stimulated phenotype switching and resistance to the clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fbcc4dfdc14a08c4b4006f746f2834f
https://hdl.handle.net/10037/18712